Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
depulfavirine long-acting injectable
- Development stage
- Phase 3
- Lead developer
- Viriom
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
VM-1500A-LAI is a long-acting injectable nanoformulation of depulfavirine (VM1500A), a non-nucleoside reverse transcriptase inhibitor (NNRTI) with broad-spectrum activity against HIV-1 variants. The formulation is designed to provide sustained therapeutic levels of the active compound over extended periods, potentially allowing for once-monthly or less frequent dosing. VM1500A has a long plasma half-life in humans (~7.5-8.9 days) and extensively partitions to blood cells, which serve as a natural slow-release depot. The nanosuspension formulation has particle sizes in the range of 380-450 nm and is designed to be readily resuspendable and easily syringeable after lyophilization.
- Other names
- deselsulfavirine long-acting injectable
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on depulfavirine long-acting injectable.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on depulfavirine long-acting injectable.